Tuesday, 27 February 2024

Moderna, Thermo Fisher announce long-term strategic collaboration for vaccine, therapies

25 February 2022 | News

Agreement to leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies

image credit- shutterstock

image credit- shutterstock

Moderna, Inc. and Thermo Fisher Scientific Inc. have announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the US of Spikevax, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline.

Over the past several years, Thermo Fisher has been partnering with Moderna to support its development pipeline with both clinical research and contract manufacturing services. This included the quick scale-up of aseptic fill-finish services and packaging of its COVID-19 vaccine.

As part of this expanded agreement, Thermo Fisher will now provide dedicated capacity for a range of aseptic fill-finish services including lyophilized and liquid filling. In addition, the company will provide inspection, labeling and final packaging services.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account